Exchange Capital Management Inc. Purchases 1,095 Shares of The Clorox Company $CLX

Exchange Capital Management Inc. lifted its position in shares of The Clorox Company (NYSE:CLX) by 11.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,871 shares of the company’s stock after purchasing an additional 1,095 shares during the period. Exchange Capital Management Inc.’s holdings in Clorox were worth $1,305,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of CLX. Vanguard Group Inc. lifted its holdings in Clorox by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 15,573,076 shares of the company’s stock worth $2,293,135,000 after buying an additional 65,924 shares during the period. Northern Trust Corp lifted its stake in Clorox by 2.3% in the first quarter. Northern Trust Corp now owns 1,528,920 shares of the company’s stock worth $225,133,000 after acquiring an additional 34,655 shares during the period. Invesco Ltd. boosted its holdings in Clorox by 7.4% in the first quarter. Invesco Ltd. now owns 1,361,710 shares of the company’s stock valued at $200,512,000 after acquiring an additional 94,371 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Clorox by 3.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,157,257 shares of the company’s stock valued at $170,406,000 after purchasing an additional 41,485 shares during the period. Finally, Hsbc Holdings PLC raised its holdings in Clorox by 118.8% in the 1st quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company’s stock worth $159,699,000 after purchasing an additional 589,544 shares in the last quarter. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Citigroup reaffirmed a “neutral” rating and set a $135.00 target price (down previously from $140.00) on shares of Clorox in a research note on Tuesday, July 15th. UBS Group cut their price objective on Clorox from $150.00 to $134.00 and set a “neutral” rating on the stock in a research report on Thursday, July 17th. Wells Fargo & Company decreased their target price on Clorox from $130.00 to $125.00 and set an “equal weight” rating for the company in a research report on Thursday, September 25th. TD Cowen dropped their price target on Clorox from $120.00 to $117.00 and set a “hold” rating on the stock in a research report on Wednesday. Finally, JPMorgan Chase & Co. upped their price target on Clorox from $133.00 to $135.00 and gave the stock a “neutral” rating in a research note on Monday, September 8th. One equities research analyst has rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Clorox currently has an average rating of “Reduce” and an average target price of $134.08.

Clorox Stock Performance

Shares of CLX opened at $122.25 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15. The stock has a market cap of $14.95 billion, a P/E ratio of 18.75, a P/E/G ratio of 0.98 and a beta of 0.52. The business’s 50 day moving average price is $122.96 and its 200-day moving average price is $129.78. The Clorox Company has a 52 week low of $116.53 and a 52 week high of $171.37.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.24 by $0.63. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The business had revenue of $1.99 billion during the quarter, compared to analysts’ expectations of $1.94 billion. During the same quarter in the previous year, the business earned $1.82 earnings per share. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Equities research analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 6th. Investors of record on Wednesday, October 22nd will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend is Wednesday, October 22nd. Clorox’s dividend payout ratio is 76.07%.

Insider Buying and Selling

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the sale, the chief operating officer directly owned 54,221 shares in the company, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.57% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.